Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

By rosiglitazone Medication Trial Investigators, Theodora S Temelkova-Kurktschiev, H. Gerstein, S. Yusuf, J. Bosch, Janice Pogue, P. Sheridan, N. Dinççağ, M. Hanefeld, B. Hoogwerf and 5 more. The Lancet, 2006

1,710 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/138e388ce59352ef39806fbe5394d02e79c4e657

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. S. Grundy
2. R. Eckel
3. P. Zimmet

In Molecular Biology

1. S. Grundy
2. P. Zimmet

Citations in the corpus

• The metabolic syndrome. (2003, positive): “In the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial, rosiglitazone reduced the risk of diabetes or death by 60% in individuals with IFG or IGT and no previous cardiovascular disease [92].”